Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL

Leukemia. 2022 May;36(5):1361-1370. doi: 10.1038/s41375-022-01545-w. Epub 2022 Mar 28.


Fit patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) in relapsed or refractory (R/R) disease status often receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHCT) or allogeneic HCT (alloHCT). However, there is no consensus on the type of HCT that should be applied for such patients. Herein, we retrospectively evaluated the survival outcome of 760 adult R/R PTCL-NOS or AITL patients who underwent the first HCT. Among them, 318 relapsed after first remission (REL) and 442 were refractory to the primary therapy (PIF). The 4-year overall survival (OS) of autoHCT and alloHCT was 50 and 50% for REL patients, and 52 and 49% for PIF patients, respectively. In the multivariable analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL (hazard ratio [HR] 0.74; 95% confidence interval [CI]: 0.53-1.03), and significantly better PFS in PIF (HR 0.64; 95% CI: 0.46-0.88) compared with autoHCT. The subgroup analysis with propensity-score matching showed that alloHCT was associated with better OS for REL-sensitive and PIF-nonremission disease. This study suggested that the advantage of alloHCT for R/R PTCL-NOS or AITL is different, depending on the disease status at HCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunoblastic Lymphadenopathy*
  • Lymphoma, T-Cell, Peripheral* / pathology
  • Retrospective Studies
  • Transplantation, Autologous